Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers

Drug Metabolism and Disposition

Volumn 37, Issue 8, 2009, Pages 1759-1768

  Izukawa, Takeshi ^a   Nakajima, Miki ^a   Fujiwara, Ryoichi ^a   Yamanaka, Hiroyuki ^a   Fukami, Tatsuki ^a   Takamiya, Masataka ^b   Aoki, Yasuhiro ^b   Ikushiro, Shin Ichi ^c   Sakaki, Toshiyuki ^c   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

^c TOYAMA PREFECTURAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A5; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B10; GLUCURONOSYLTRANSFERASE 2B11; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B17; GLUCURONOSYLTRANSFERASE 2B28; GLUCURONOSYLTRANSFERASE 2B4; GLUCURONOSYLTRANSFERASE 2B7; GLYCERALDEHYDE 3 PHOSPHATE; MESSENGER RNA; OXIDOREDUCTASE; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE;

ARTICLE; CONTROLLED STUDY; GLUCURONIDATION; HUMAN; HUMAN TISSUE; LIVER; MICROSOME; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REACTION ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

BLOTTING, WESTERN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC VARIATION; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; LIVER; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 67650821911     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.027227     Document Type: Article

References (36)

1. Aueviriyavit S, Furihata T, Morimoto K, Kobayashi K, and Chiba K (2007) Hepatocyte nuclear factor 1 alpha and 4 alpha are factors involved in interindividual variability in the expression of UGT1A6 and UGT1A9 but not UGT1A1, UGT1A3 and UGT1A4 mRNA in human livers. Drug Metab Pharmacokinet 22:391-398.
2. Barbier O, Girard H, Inoue Y, Duez H, Villeneuve L, Kamiya A, Fruchart JC, Guillemette C, Gonzalez FJ, and Staels B (2005) Hepatic expression of the UGT1A9 gene is governed by hepatocyte nuclear factor 4α. Mol Pharmacol 67:241-249.
3. Beaulieu M, Lévesque E, Hum DW, and Bélanger A (1998) Isolation and characterization of human orphan UDP-glucuronosyltransferase, UGT2B11. Biochem Biophys Res Commun 248:44-50.
4. Bernard P, Goudonnet H, Artur Y, Desvergne B, and Wahli W (1999) Activation of the mouse TATA-less and human TATA-containing UDP- glucuronosyltransferase 1A1 promoters by hepatocyte nuclear factor 1. Mol Pharmacol 56:526-536.
5. Congiu M, Mashford ML, Slavin JL, and Desmond PV (2002) UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos 30:129-134.
6. Court MH, Hazarika S, Krishnaswamy S, Finel M, and Williams JA (2008) Novel polymorphic human UDP-glucuronosyltransferase 2A3: cloning, functional characterization of enzyme variants, comparative tissue expression, and gene induction. Mol Pharmacol 74:744-754.
7. Erichsen TJ, Ehmer U, Kalthoff S, Lankisch TO, Müller TM, Munzel PA, Manns MP, and Strassburg CP (2008) Genetic variability of aryl hydrocarbon receptor (AhR)-mediated regulation of the human UDP glucuronosyltransferase (UGT) 1A4 gene. Toxicol Appl Pharmacol 230:252-260.
8. Finel M, Li X, Gardner-Stephen D, Bratton S, Mackenzie PI, and Radominska-Pandya A (2005) Human UDP-glucuronosyltransferase 1A5: identification, expression, and activity. J Pharmacol Exp Ther 315:1143-1149.
9. Fisher MB, Paine MF, Strelevitz TJ, and Wrighton SA (2001) The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273-297.
10. Fujiwara R, Nakajima M, Yamanaka H, Nakamura A, Katoh M, Ikushiro S, Sakaki T, and Yokoi T (2007) Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms. Drug Metab Dispos 35:747-757.
11. Gardner-Stephen DA and Mackenzie PI (2007) Hepatocyte nuclear factor1 transcription factors are essential for the UDP-glucuronosyltransferase 1A9 promoter response to hepatocyte nuclear factor 4α. Pharmacogenet Genomics 17:25-36.
12. Gong QH, Cho JW, Huang T, Potter C, Gholami N, Basu NK, Kubota S, Carvalho S, Pennington MW, Owens IS, et al. (2001) Thirteen UDP glucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 11:357-368.
13. Gregory PA, Lewinsky RH, Gardner-Stephen DA, and Mackenzie PI (2004) Coordinate regulation of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 genes by hepatocyte nuclear factor 1αand the caudal-related homeodomain protein 2. Mol Pharmacol 65:953-963.
14. Guillemette C, De Vivo I, Hankinson SE, Haiman CA, Spiegelman D, Housman DE, and Hunter DJ (2001) Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels. Cancer Epidemiol Biomarkers Prev 10:711-714.
15. Ikushiro S, Emi Y, Kato Y, Yamada S, and Sakaki T (2006) Monospecific antipeptide antibodies against human hepatic UDP-glucuronosyltransferase 1A subfamily (UGT1A) isoforms. Drug Metab Pharmacokinet 21:70-74.
16. Ishii Y, Hansen AJ, and Mackenzie PI (2000) Octamer transcription factor-1 enhances hepatic nuclear factor-1α-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter. Mol Pharmacol 57:940-947.
17. Itäaho K, Court MH, Uutela P, Kostiainen R, Radominska-Pandya A, and Finel M (2009) Dopamine is a low affinity and high specificity substrate for the human UDP-glucuronosyltransferase 1A10. Drug Metab Dispos 37:768-775.
18. Kaivosaari S, Toivonen P, Hesse LM, Koskinen M, Court MH, and Finel M (2007) Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10. Mol Pharmacol 72:761-768.
19. Karypidis AH, Olsson M, Andersson SO, Rane A, and Ekström L (2008) Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate. Pharmacogenomics J 8:147-151.
20. Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, and Court MH (2005) UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 5′-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation. J Pharmacol Exp Ther 313:1331-1339.
21. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685.
22. Nakamura A, Nakajima M, Higashi E, Yamanaka H, and Yokoi T (2008a) Genetic polymorphisms in the 5′-flanking region of human UDP-glucuronosyltransferase 2B7 affect the Nrf2-dependent transcriptional regulation. Pharmacogenet Genomics 18:709-720.
23. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, and Yokoi T (2008b) Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36:1461-1464.
24. Ohno S and Nakajin S (2009) Determination of mRNA expression of human UGTs and application for localization in various human tissues by real time RT-PCR. Drug Metab Dispos 37:32-40.
25. Ramírez J, Mirkov S, Zhang W, Chen P, Das S, Liu W, Ratain MJ, and Innocenti F (2008) Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver. Pharmacogenomics J 8:152-161.
26. Strassburg CP, Kneip S, Topp J, Obermayer-Straub P, Barut A, Tukey RH, and Manns MP (2000) Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 275:36164-36171.
27. Strassburg CP, Manns MP, and Tukey RH (1997a) Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res 57:2979-2985.
28. Strassburg CP, Oldhafer K, Manns MP, and Tukey RH (1997b) Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 52:212-220.
29. Sugatani J, Yamakawa K, Yoshinari K, Machida T, Takagi H, Mori M, Kakizaki S, Sueyoshi T, Negishi M, and Miwa M (2002) Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun 292:492-497.
30. Tabata T, Katoh M, Tokudome S, Hosakawa M, Chiba K, Nakajima M, and Yokoi T (2004) Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5′-deoxy-5-fluorocytidine formation. Drug Metab Dispos 32:762-767.
31. Tukey RH and Strassburg CP (2001) Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 59:405-414.
32. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
33. Wells PG, Mackenzie PI, Chowdhury JR, Guillemette C, Gregory PA, Ishii Y, Hansen AJ, Kessler FK, Kim PM, Chowdhury NR, et al. (2004) Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab Dispos 32:281-290.
34. Wilson W 3rd, Pardo-Manuel de Villena F, Lyn-Cook BD, Chatterjee PK, Bell TA, Detwiler DA, Gilmore RC, Valladeras IC, Wright CC, Threadgill DW, et al. (2004) Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 84:707-714.
35. Zheng Z, Fang JL, and Lazarus P (2002) Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues. Drug Metab Dispos 30:397-403.
36. Zhou J, Zhang J, and Xie W (2005) Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyltransferases. Curr Drug Metab 6:289-298.